Impact of Promotions on Awareness,Trial,and Likelihood of Trial of New Dissolvable Tobacco

Abstract

Purpose.

To determine test market awareness and promotional effects of Camel dissolvable tobacco.

Design.

Cross-sectional survey.

Setting.

Indiana test market.

Subjects.

Stratified sample of Indiana adults (N = 472).

Measures.

Data were poststratified and weighted to account for the sampling and demographics.

Analysis.

Descriptive statistics and multivariate analysis.

Results.

The study results indicate that 31.2% of participants were aware of Camel Dissolvables, 4.5% had tried them, and 8.3% were likely to try them. Tobacco use was a significant predictor of all outcomes; dual (cigarettes and smokeless tobacco) users were more likely to be familiar with, try, and be interested in trying Camel Dissolvables than single tobacco users and nonusers (p < .05). Male gender was a significant predictor only for likelihood of trial (p < .05). Education was a significant predictor only of actual trial (p < .05). Familiarity was predicted by in-store, magazine, and mail promotions. Trial was predicted by having seen magazine ads. Web site exposure predicted likelihood of trial. Of those who reported trying Camel Dissolvables (N = 37), 49% no longer used them, 43% used them some days, and 8% used them daily. Continued use was reported by 87% of dual users and 26% of single tobacco users (p < .01).

Conclusion.

Smokers and male dual tobacco users appear most affected by Camel Dissolvables promotions.

Keywords

Dissolvable Tobacco Smokeless Tobacco Dual Tobacco Use Promotion Prevention Research Manuscript format: research Research purpose: relationship testing evaluation Study design: cross-sectional survey Outcome measures: reported awareness/familiarity trial and likelihood of trial of Camel dissolvable tobacco Setting: Indiana test market Health focus: tobacco use Target population age: adults Target population circumstances: education geographic location gender

Get full access to this article

View all access options for this article.

References

Centers for Disease Control and Prevention . Cigarette smoking among adults—United States, 2007. MMWR. 2008;57:1221–1226.

Centers for Disease Control and Prevention . Slightly lower adult smoking rates. 2008. Available at: http://www.cdc.gov/media/pressrel/2008/r081113.htm. Accessed November 13, 2008.

Reynolds American . Reynolds American completes acquisition of Conwood, 2006. Available at: http://www.prnewswire.com/news-releases/reynoldsamerican-completes-acquisition-of-conwood-56588657.html. Accessed October 10, 2010.

Altria Group Inc. Altria Group, Inc. agrees to acquire UST Inc. , world's leading moist smokeless tobacco manufacturer, for $69.50 per share in cash. 2008. Available at: http://www.altria.com/en/cms/company_announcements/announcement.aspx?reqId=1194435. Accessed October 10, 2010.

Beirne

. R. J. Reynolds preps dissolvable tobacco. Brandweek. October 8, 2010. Available at: http://www.brandweek.com/bw/content_display/news-andfeatures/packaged-goods/e3i3a362ca17e5cae6357fbfa0580a2bbee. Accessed December 27, 2010.

Rainey

Conder

Goodpaster

. Chemical characterization of dissolvable tobacco products promoted to reduce harm. J Agric Food Chem. 2011;59:2745–2751.

R.J. Reynolds . Statement regarding Camel Dissolvables tobacco products, June 2010. Available at: http://www.rjrt.com/uploadedFiles/Content/Global/ResponseStatementToCamelDissolvablesMisrepresentations.pdf. Accessed October 13, 2010.

Romito

Saxton

Coan

Christen

. Retail promotions and perceptions of R.J. Reynolds' novel dissolvable tobacco in a US test market. Harm Reduct J. 2011;8(1):1–10.

Stepanov

Jensen

Hatsukami

Hecht

. New and traditional smokeless tobacco: A comparison of toxicant and carcinogen levels. Nicotine Tob Res. 2008;10:1773–1782.

10.

Stepanov

Biener

Knezevich

. Monitoring tobacco-specific n-nitrosamines and nicotine in novel Marlboro and Camel smokeless tobacco products: Findings from round 1 of the new product watch. Nicotine Tob Res. 2011;14:274–281.

11.

Liu

Nemeth

Klein

. Adolescent and adult perceptions of traditional and novel smokeless tobacco products and packaging in rural Ohio. Tob Control. In press.

12.

Choi

Fabian

Mottey

. Young adults' favorable perceptions of snus, dissolvable tobacco products, and electronic cigarettes: Findings from a focus group study. Am J Public Health. 2012;102:2088–2093.

13.

US Food and Drug Administration . Final summary on dissolvable tobacco products. Tobacco Products Scientific Advisory Committee Reports. March 2012. Available at: http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/TobaccoProductsScientificAdvisoryCommittee/ucm281322.htm. Accessed June 25, 2012.

14.

Carver

. Report: Dissolvable tobacco has greatly reduced risks. Winston-Salem J. March 2012. Available at: http://www2.journalnow.com/blogs/business-beat/2012/mar/22/report-dissolvable-tobacco-has-greatly-reduced-ris-ar-2075012/. Accessed June 25, 2012.

15.

Schwartz

Brunnemann

Adami

. Brand specific responses to smokeless tobacco in a rat lip canal model. J Oral Path Med. 2010;39:453–459.

16.

Mendoza-Baumgart

Tulunay

Hecht

. Pilot study on lower nitrosamine smokeless tobacco products compared with medicinal nicotine. Nicotine Tob Res. 2007;9:1309–1332.

17.

Levy

Mumford

Cummings

. The relative risks of a low-nitrosamine smokeless tobacco product compared with smoking cigarettes: Estimates of a panel of experts. Cancer Epidemiol Biomarkers Prev. 2004;13:2035–2042.

18.

Gartner

Hall

. Harm reduction policies for tobacco users. Int J Drug Policy. 2010;21:129–130.

19.

Rodu

Godshall

. Tobacco harm reduction: An alternative cessation strategy for inveterate smokers. Harm Reduct J. 2006;3:37.

20.

Hatsukami

Lemmonds

Tomar

. Smokeless tobacco use: Harm reduction or induction approach? Prev Med. 2004;38:309–317.

21.

Tomar

. Epidemiologic perspectives on smokeless tobacco marketing and population harm. Am J Prev Med. 2007;33(S6):387–397.

22.

Wetter

McClure

de Moor

. Concomitant use of cigarettes and smokeless tobacco: Prevalence, correlates, and predictors of tobacco cessation. Prev Med. 2002;34:638–648.

23.

Teo

Ounpuu

Hawken

; INTERHEART Study Investigators. Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: A case-control study. Lancet. 2006;19:647–658.

24.

Mejia

Ling

Glantz

. Quantifying the effects of promoting smokeless tobacco as a harm reduction strategy in the USA. Tob Control. 2012;19:297–305.

25.

Mejia

Ling

. Tobacco industry consumer research on smokeless tobacco users and product development. Am J Public Health. 2010;100:78–87.

26.

Freiberg

. Federal approaches to the regulation of noncigarette tobacco products. Am J Prev Med. 2012;43(5 suppl. 3):S249–S254.

27.

Regan

Dube

Arrazola

. Smokeless and flavored tobacco products in the US: 2009 styles survey results. Am J Prev Med. 2012;42:29–36.

28.

McMillen

Maduka

Winickoff

. Use of emerging tobacco products in the United States. J Environ Public Health. 2012:1–8.

29.

Southwell

Kim

Tessman

. The marketing of dissolvable tobacco: Social science and public policy research needs. Am J Health Promot. 2012;26:331–332.

30.

Biener

Bogen

. Receptivity to Taboka and Camel Snus in a US test market. Nicotine Tob Res. 2009;11:1154–1159.

31.

Madden

Zickuhr

. 65% of online adults use social networking sites. Pew Internet & American Life Project, 2011. Available at: http://pewinternet.org/Reports/2011/Social-networking-Sites.aspx. Accessed June 20, 2012.

32.

Tobacco Commons . New Camel Dissolvable package and product redesign. 2011. Available at: http://tobaccocommons.com/2011/04/08/new-camel-dissolvable-package-and-product-redesign/. Accessed June 28, 2012.

33.

Seidenberg

Rees

Connolly

. RJ Reynolds goes international with new dissolvable tobacco products. Tob Control. 2012;21:368–369.